Prof. Jean-François Dufour studied mathematics at the University of Geneva, Switzerland, and received his medical degree from the Geneva Medical School. After training in internal medicine at the University Hospital Geneva and the University Hospital Bern, he joined the laboratory of Professor I. Arias at Tufts University in Boston, Massachusetts, USA where he studied the effects of calcium signaling on bile canaliculus. He then returned to the clinic to complete a gastroenterology fellowship with Professor M. Kaplan at the New England Medical Center and Tufts University. In 1997, Professor Dufour established his own laboratory at the University of Bern. He was the Clinic Director and Full Professor of Hepatology from 2011 to 2021. He transformed the Liver Unit into a national and international center of excellence for liver diseases. He is now director of the Centre des Maladies Digestives in Lausanne. Professor Dufour is a member of the AASLD, AGA, EASL, ACG, the Swiss Association for the Study of the Liver, and the Schweizerische Gesellschaft für Gastroenterologie und Hepatologie. He is a founding member of the International Liver Cancer Association. He was twice a member of the Governing Board of EASL as a Scientific Committee Member and then as Educational Councillor. He was also a member of the UEG Educational Committee. Professor Dufour has a broad understanding of basic, translational and clinical research, its bottlenecks and the challenges in disseminating and exploiting knowledge. Professor Dufour has served as the principal investigator on multiple clinical studies, focusing on NASH and HCC. His laboratory explores the link between the fatty liver, physical activity and liver cancer. He was/is an Associate Editor of the Journal of Hepatology, Hepatology (section Highlights), GUT, Liver International and Clinical Sciences. Professor Dufour has published more than 300 peer-reviewed publications

Prof. Jean-François Dufour studied mathematics at the University of Geneva, Switzerland, and received his medical degree from the Geneva Medical School. After training in internal medicine at the University Hospital Geneva and the University Hospital Bern, he joined the laboratory of Professor

Cancers and NASH
Patients and physicians have to know that NASH increases the risk to develop cancers. Specific surveillance has to be implemented when indicated. Hepatocellular carcinoma is rare in patients with NASH without advanced fibrosis, but seems to occur not rarely when the liver is not yet cirrhotic. Some molecular mechanisms seem specific to NASH-related HCC. The management is similar to HCC with other underlying liver disease. Patients with NASH-related HCC may respond less to immuno-oncology.
Read More
Cancers and NASH
Dr. Jean-François Dufour (Switzerland) reviews the association between cancers and NASH, where he highlights the causes of death in NAFLD patients, in which cardiovascular diseases and non-liver cancer with 38.3% and 18.7% are identified as some of the major causes.
Read More
PPARs: State-of-the-art by Prof. J.-F. Dufour
Prof. Jean-François Dufour (Switzerland) explores PPARs to NAFLD28 as a systemic disease with metabolic changes in Adipose tissue, skeletal muscle, liver and endothelium.
Read More
The role of comorbidities in NASH management: a holistic approach
Prof Jean-François Dufour, Switzerland, addresses the important problem of comorbidities in NASH management including diabetes, cardiovascular disease, cancer. This video was filmed in Boston during the Liver meeting 2019.
Read More
Prof Jean-François Dufour highlights why the Liver meeting 2019 in Boston is relevant for NASH investigators with presentations of new modes of action and non-invasive biomarkers.
This liver meeting in 2019 is quite interesting for those…

Prof Dufour discusses best practices about the diagnosis of NASH
Read More
Is NASH only about the liver ?
Prof Jean-François Dufour, Switzerland sheds lights on this important question.
Read More